short-acting insulin


Also found in: Dictionary, Thesaurus, Encyclopedia.

short-acting insulin

a clear preparation of regular (crystalline zinc) insulin with an immediate (15 to 30 minutes) onset of action that reaches a peak of action in 2 to 4 hours. The duration of action is 6 to 8 hours. There is considerable variation in individual patients and with different doses in the same patient. Therefore these data should be considered only as rough guidelines. Also called rapid-acting insulin. Compare intermediate-acting insulin, long-acting insulin. See also insulin.
References in periodicals archive ?
If needed, blood glucose can be controlled with small doses of supplemental short-acting insulin.
The current research is looking at short-acting insulin and those using long-acting insulin injections would have to continue taking these.
For some type 2 patients with sufficient [beta]-cell function, one or two injections of Levemir will be adequate, but those with more advanced disease will also need short-acting insulin at meals, he noted.
One unit of short-acting insulin will lower her blood glucose level by approximately 30 mg/dL.
Rizvi (9) presents a concise review of the modern approach to treating type 2 diabetes, characterized by aggressive use of multi-oral-drug regimens early in the disease process and, when needed, the use of very long-acting insulin supplemented by very short-acting insulin to mimic the natural insulin secretion of the pancreas.
The goal of Halozyme's Insulin-PH20 program is to develop a rapid and short-acting insulin product that would more closely mimic the mealtime insulin release that occurs in non-diabetics that could lead to improved treatment for diabetes patients.
Short-acting insulin analogues are safe and optimal for use in insulin-requiring diabetic pregnancies, but there are not enough data yet to recommend the new long-acting analogues for pregnant women, Dr.
When the ability to maintain control with oral agents during the day is lost, control can be achieved with two injections of mixed insulin in the morning and at dinnertime; or injection of a short-acting insulin before each meal with the basal insulin provided by glargine.
A rapid and short-acting insulin profile would more closely mimic the mealtime insulin release that occurs in non-diabetics and could lead to improved treatment for diabetes patients.
All had maintained good glucose control for 2 months prior to the study period with a stable regimen of at least two subcutaneous injections of short-acting insulin or an insulin analogue during the day plus one nocturnal injection of long-acting insulin.
Lantus can be used in patients who are candidates for an overnight dose of NPH or ultralente, in combination with regular insulin or the more rapidly acting Humalog (lispro insulin) before meals in type 1 diabetics, and with short-acting insulin or oral agents in type 2 diabetics, he advised.